News
The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...
Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...
8h
Zacks Investment Research on MSNCan Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...
Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...
Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...
Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...
During a 72-week study, those taking the highest dose of orforglipron lost an average of 27.3 pounds. While injections might cause people to lose more weight, a pill has advantages over them, ...
In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results